


**Heartseed CEO Keiichi Fukuda Delivers Keynote on  
Advanced Cell Therapy and Regenerative Medicine in Taiwan**  
- Deepening International Collaboration through Invited Lecture  
at Taichung Veterans General Hospital-

**Tokyo, Japan, February 29, 2023 – Keiichi Fukuda, CEO of Heartseed Inc., delivered a prestigious invited lecture at Taichung Veterans General Hospital in Taichung City, Taiwan, on February 19, 2024. The event was part of an initiative to advance the latest in cell therapy and regenerative medicine in Taiwan, aimed at incorporating global insights for Taiwanese medical professionals and researchers.**

Dr. Fukuda was invited by the Superintendent Dr. Shih-Ann Chen of Taichung Veterans General Hospital (TCVGH), a world-class cardiology expert, to share his cutting-edge research results with staffs in TCVGH. In his address, Fukuda presented groundbreaking research advancements in cardiac regenerative medicine, sparking lively discussions among Taiwanese medical stakeholders. The dialogue was particularly focused on Heartseed's innovative cell therapy technologies, such as HS-001, which garnered significant attention from attendees.

Taiwan is actively working on legal frameworks to industrialize regenerative medicines, drawing inspiration from Japan's strides in the field. The collaboration between Japan and Taiwan in this sector is highly anticipated. In March 2023, The Foundation of Medical Professionals Alliance in Taiwan signed a Memorandum of Understanding (MOU) with the Japanese Society for Regenerative Medicine to foster cooperative ties. Given these circumstances, Fukuda's lecture represents a pivotal moment in strengthening the bilateral relationship in healthcare innovation.

Dr. Wen-Lieng Lee, Director of the Cardiovascular Center, shared his enthusiasm about the potential for collaboration, stating, "Every step in Dr. Fukuda's ingenious cell therapy is deeply rooted in solid science and a thorough understanding of both basic and clinical medicines. We are fascinated by every study embedded in the complete story and really inspired by his personal charisma and the perfect teamwork. Though it is still in the clinical trial stage, we do see some bright light on the horizon. If there is any chance, we do hope that we can collaborate with each other to extend blessings to more patients in the future."



Superintendent Dr. Shih-Ann Chen also presented Dr. Fukuda with a commemorative gift after his one-hour speech. The Deputy Superintendent Dr. Fu and the Director of the Cell Therapy Center Dr. Lee also personally led a tour of the GTP laboratory and cardiac catheterization rooms. In response to the overwhelming enthusiasm for regenerative medicine in TCVGH and the high level of research in the field, Dr. Fukuda expressed his admiration, stating, "I am deeply impressed by the passion for regenerative medicine in Taiwan and the high standard of research in this field. I look forward to deepening medical cooperation between our two countries."



### About Taichung Veterans General Hospital

Located in the heart of Taichung City in central Taiwan, Taichung Veterans General Hospital is a national healthcare institution boasting 1,622 beds and approximately 4,500 medical staff members. The hospital is renowned for its exceptional research and development programs and advanced medical facilities, ensuring the provision of safe and high-quality medical services. It accommodates around 7,700 outpatients and 160 emergency cases daily, catering to a wide range of medical needs.

The hospital is also committed to advancing research and development in cutting-edge cell therapy and regenerative medicine. In October last year, it established the "Good Tissue Practice (GTP) Laboratory." The center comprises a team of 40 specialists in various diseases, including cancer, autoimmune diseases, neurological disorders, and degenerative joint diseases, aiming to offer state-of-the-art treatments, including cell therapy.

In October last year, during the hospital's 41st anniversary, President Tsai visited and commended Taichung Veterans General Hospital for being selected as one of the world's top smart hospitals for the second consecutive year under the leadership of Superintendent Shih-Ann Chen. The president praised the hospital's remarkable achievements in both intelligent and precision medicine.

### About Heartseed

Heartseed Inc. was founded in 2015 to develop and commercialize cardiac remuscularization therapy developed by Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo, Japan. Heartseed has proprietary technologies throughout the entire manufacturing process of the cardiomyocyte-cell product, including purification, cell delivery and iPSC production.

Heartseed announced the global collaboration and license agreement with Novo Nordisk A/S for HS-001 in June 2021. Heartseed received "Minister of Science and Technology Policy Award" at Japan Venture Awards 2021 and "Ministry of Education, Culture, Sports, Science and Technology Award" at Academic Startups 2021, and "Most Promising Pipelines Awards (iPSC)" at Asia Pacific Cell & Gene Therapy Excellence Awards 2022. For more information, visit [heartseed.jp](https://heartseed.jp), [LinkedIn](#) and [YouTube](#).

---

### Contact

Kikuo Yasui  
COO, Heartseed Inc.  
5F Seavance S Building, 1-2-3 Shibaura, Minato-ku,  
Tokyo 105-0023, Japan  
E-mail: [kikuo.yasui@heartseed.jp](mailto:kikuo.yasui@heartseed.jp)